trending Market Intelligence /marketintelligence/en/news-insights/trending/L0y-Xjp2y1bPNuFDW3aNRg2 content esgSubNav
In This List

Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Ligand Pharmaceuticals closes acquisition of Crystal Bioscience

Ligand Pharmaceuticals Inc. closed its acquisition of privately held Crystal Bioscience Inc. for an initial consideration of about $25 million in cash.

Crystal is now a wholly owned subsidiary of Ligand.

According to the merger agreement, Crystal shareholders will also receive up to $10.5 million in milestone payments and revenue sharing from existing licensees for a defined period.